USFDA nod to Gland Pharma Latanoprost Ophthalmic Solution

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-12-03 09:00 GMT | Update On 2024-12-03 09:00 GMT

Hyderabad: Gland Pharma Limited, a generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill).

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan, latanoprost ophthalmic solution 0.005% (50 μg/mL) held by UPJOHN

US 2 LLC.

This Product is used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with openangle glaucoma or ocular hypertension. The Company expects to launch this Product through its marketing partners in FY25.

Read also: Aurobindo Pharma, Dr Reddy's Labs and 4 others partner with Telangana to set up facilities in Pharma City

According to IQVIA, the product had US sales of approximately USD 111.6 million for the twelve months ending December 2023.

Medical Dialogues team had earlier reported that Gland Pharma Limited, had received tentative approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution, 0.024%.

Read also: Gland Pharma bags tentative USFDA nod for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and develops, manufactures, and markets sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

USFDA nod to Gland Pharma Latanoprost Ophthalmic Solution

Similar News

Granules India arm gets 1 USFDA observation for Hyderabad facility

CDSCO Panel Clears PURE & CURE's Sickle Cell Trial With Conditions On Sample Size, Sites

Sun Pharma net profit drops 20% to Rs 2,279 crore in Q1

Sandoz to acquire Just-Evotec Biologics EU SAS in-house development, manufacturing capabilities in France

Zydus Wellness sees exit of Head-R&D, Head-GDSO

Natco Pharma appoints TC Mallikarjun as Vice President - QC at Kothur Pharma Division

Veeda Clinical Research Gets Expert Committee Nod To Conduct BA/BE Study Of Ibrutinib For Export

Ajanta Pharma Gets Relief in Erectile Dysfunction Drug Export Case, Penalty Set Aside